Tangel Matthew R, Rastinehad Ardeshir R
Department of Radiology, Mount Sinai Health System, New York, NY, 10003, USA.
Department of Interventional Radiology, Mount Sinai Health System, New York, NY, 10003, USA.
F1000Res. 2018 Aug 24;7. doi: 10.12688/f1000research.14498.1. eCollection 2018.
Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future.
近年来,医学成像领域取得了许多令人振奋的进展,这些进展将改变我们诊断、分期和治疗前列腺癌患者的方式。多参数磁共振成像(MRI)正成为前列腺癌成像的主要方式。对于无法进行MRI检查的患者,超声造影和剪切波弹性成像可能是强有力的替代方法。前列腺特异性膜抗原导向的正电子发射断层扫描/计算机断层扫描已被证明在高危疾病的初始分期以及检测生化复发患者的疾病方面具有重要价值。随着越来越多的研究不断涌现,很明显,前列腺癌诊断和分期的标准算法在不久的将来将发生重大变化。